News | Intensity Modulated Radiation Therapy (IMRT) | March 14, 2022

Recent progress includes feasibility study completion and nearly 2,000 patient treatments

RefleXion Medical, a therapeutic oncology company pioneering the use of biology-guided radiotherapy (BgRT) for all stages of cancer, today announced the close of an $80 million equity financing.

March 14, 2022 — RefleXion Medical, a therapeutic oncology company pioneering the use of biology-guided radiotherapy (BgRT) for all stages of cancer, today announced the close of an $80 million equity financing. In addition to participation from RefleXion’s existing investors, the company also welcomes investments from Ascension Ventures, Catalio Capital Management, Sixty Degree Capital and Hillenbrand Capital Partners.

“RefleXion’s breakthrough technology holds the potential to expand the reach of radiotherapy to late-stage cancers where five-year survival is less than 31%,” said Tara Butler, M.D., senior managing director of Ascension Ventures. “We believe wholeheartedly in their goals of improving outcomes for these patients, and in prioritizing the availability of BgRT at community hospitals thereby enabling patients to receive their cancer treatment without traveling long distances.”

Existing RefleXion investors that participated in the round include TPG’s The Rise Fund, KCK Group, PSP Investments, T. Rowe Price, Ally Bridge Partners, Venrock, and global pharmaceutical leaders, Pfizer Ventures and Johnson & Johnson Innovation, JJDC Inc.

BgRT is the first and only technology designed to transform an injected radiotracer into a unified motion management solution that overcomes the technical limitations currently restricting radiotherapy use to one or two tumors. RefleXion’s BgRT recently received Breakthrough Device designation from the U.S. Food and Drug Administration (FDA) for use in lung tumors because of its potential to detect and then immediately treat moving targets. The company aims to one day scale BgRT to treat all visible cancer sites to create a new treatment option for patients with metastatic disease. 

“The steadfast belief in RefleXion’s vision by our investor syndicate gives us the runway to drive hard and fast toward developing our platform for indications where radiotherapy was previously considered palliative only,” said Todd Powell, president and CEO of RefleXion. “In just under a year, we have gained experience with image-guided radiotherapy by delivering nearly 2,000 patient treatments, successfully completed our feasibility study, secured an additional key radiopharmaceutical agreement, and expanded our commercial footprint. 

“These important milestones lay the foundation for our future introduction of biology-guided radiotherapy,” concluded Powell.

For more information: https://reflexion.com/


Related Content

News | Lung Imaging

October 2, 2023 — A novel liquid biopsy test may help determine which patients with non-small cell lung cancer that has ...

Time October 02, 2023
arrow
News | Radiation Therapy

October 2, 2023 — A type of head and neck cancer predominantly diagnosed in people who reside in low- and middle-income ...

Time October 02, 2023
arrow
News | Radiation Oncology

October 2, 2023 — Two liquid biopsy tests that look for the presence of human papillomavirus (HPV) in the blood ...

Time October 02, 2023
arrow
News | Prostate Cancer

October 1, 2023 — The presence of a clinical navigator to act as a liaison between people with prostate cancer and the ...

Time October 01, 2023
arrow
News | ASTRO

October 1, 2023 — The 2023 Abstract Award winners have been announced by the American Society for Radiation Oncology ...

Time October 01, 2023
arrow
News | Women's Health

October 1, 2023 — In a first-of-its-kind study, people with breast cancer who underwent implant-based breast ...

Time October 01, 2023
arrow
News | Women's Health

October 1, 2023 — People who engage in sexual activity or vaginal dilation after chemoradiation treatment for cervical ...

Time October 01, 2023
arrow
News | Stereotactic Body Radiation Therapy (SBRT)

October 1, 2023 — Older adults diagnosed with kidney tumors that are not suitable for surgery may benefit from targeted ...

Time October 01, 2023
arrow
News | Information Technology

September 29, 2023 — Fuse Oncology (Fuse) a trailblazing leader in radiation oncology software solutions, unveils their ...

Time September 29, 2023
arrow
News | Prostate Cancer

September 29, 2023 — People with intermediate risk, localized prostate cancer can be treated as effectively using fewer ...

Time September 29, 2023
arrow
Subscribe Now